Shandong Lukang Pharmaceutical Co.,Ltd. (600789.SS) Bundle
Shandong Lukang Pharmaceutical's recent numbers tell a nuanced story that every investor should unpack: quarterly revenue rose to 1.47 billion CNY (Q3 2025), with TTM revenue at 6.19 billion CNY and 2024 annual revenue of 6.23 billion CNY, while market capitalization sits near 8.40 billion CNY and the stock traded at 9.35 CNY on Nov 21, 2025; profitability shows a TTM net income of 188.75 million CNY (EPS 0.21 CNY), a profit margin of 6.65% and ROE of 10.55% versus a trailing P/E around 44.20, capital structure includes a debt-to-equity ratio of 0.73 with total assets of 6.6 billion CNY and liabilities of 2.5 billion CNY alongside a 50.94% YoY rise in long-term borrowings, liquidity metrics show a current ratio of 1.20 and quick ratio of 0.77 with cash of 703.94 million CNY but a levered free cash flow of -451.72 million CNY, and key risks-centralized procurement exposure, an expected H1 2025 net income decline of 59.34%-65.98% YoY, and international currency/geopolitical exposure-sit beside growth levers such as exports to over 90 countries, three R&D centers, EU GMP/FDA certifications and a 14.36 million CNY pollution-control subsidy; dive into the full breakdown for the detailed metrics, valuation multiples (EV/EBITDA ~14.34, P/S ~1.35, P/B ~2.03) and what they mean for investment decisions
Shandong Lukang Pharmaceutical Co.,Ltd. (600789.SS) Revenue Analysis
Shandong Lukang reported quarterly revenue of 1.47 billion CNY for the quarter ending September 30, 2025, representing a sequential increase of 5.97%. Trailing twelve months (TTM) revenue is 6.19 billion CNY, up 1.79% year-over-year, and full-year 2024 revenue was 6.23 billion CNY, a 1.41% rise over 2023.- Quarterly momentum: 1.47 billion CNY (Q3 2025), +5.97% QoQ - indicates short-term demand recovery versus the prior quarter.
- TTM stability: 6.19 billion CNY, +1.79% YoY - suggests modest year-over-year growth across the most recent 12 months.
- Annual base: 2024 revenue 6.23 billion CNY, +1.41% YoY - low single-digit expansion pointing to mature market dynamics.
- Operational efficiency: revenue per employee ~969,080 CNY across 6,388 employees - useful for benchmarking productivity vs. peers.
- Valuation context: P/S ratio 1.36 with market cap 8.40 billion CNY and share price 9.35 CNY (as of 2025-11-21) - market pricing relative to sales.
| Metric | Value | Change |
|---|---|---|
| Quarterly Revenue (Q3 2025) | 1.47 billion CNY | +5.97% QoQ |
| TTM Revenue | 6.19 billion CNY | +1.79% YoY |
| Annual Revenue (2024) | 6.23 billion CNY | +1.41% YoY |
| Revenue per Employee | 969,080 CNY | 6,388 employees |
| Price-to-Sales (P/S) | 1.36 | - |
| Market Capitalization | 8.40 billion CNY | - |
| Share Price (2025-11-21) | 9.35 CNY | - |
- Investor takeaways: moderate revenue growth with positive quarter-on-quarter acceleration but only slight annual expansion; valuation (P/S 1.36) reflects modest market optimism relative to sales.
- Areas to monitor: sustainment of QoQ momentum, margin trends tied to product mix, and productivity improvements per employee.
Shandong Lukang Pharmaceutical Co.,Ltd. (600789.SS) Profitability Metrics
Shandong Lukang Pharmaceutical presents a clear snapshot of profitability that investors should weigh alongside growth expectations and valuation. Recent trailing twelve months (TTM) figures show positive net income and improving quarterly momentum, while market valuation-reflected in the trailing P/E-signals elevated expectations.- Net income (TTM): 188.75 million CNY
- Earnings per share (EPS, TTM): 0.21 CNY
- Profit margin (TTM): 6.65%
- Operating margin (TTM): 5.07%
- Return on assets (ROA): 2.10%
- Return on equity (ROE): 10.55%
- Quarterly earnings growth (YoY): 16.80%
- Trailing P/E: 44.20
- Forward P/E: Not available
| Metric | Value | Notes |
|---|---|---|
| Net Income (TTM) | 188.75 million CNY | Core profitability across last 12 months |
| EPS (TTM) | 0.21 CNY | Per-share earnings delivered to shareholders |
| Profit Margin | 6.65% | Net income / Revenue; indicates overall profitability |
| Operating Margin | 5.07% | Operating income / Revenue; reflects operational efficiency |
| ROA | 2.10% | Net income relative to total assets |
| ROE | 10.55% | Net income relative to shareholder equity |
| Quarterly Earnings Growth (YoY) | 16.80% | Recent earnings acceleration on a year-over-year basis |
| Trailing P/E | 44.20 | Market price relative to trailing EPS |
| Forward P/E | - | No forward consensus P/E available |
Shandong Lukang Pharmaceutical Co.,Ltd. (600789.SS) - Debt vs. Equity Structure
Shandong Lukang Pharmaceutical Co.,Ltd. (600789.SS) presents a capital structure characterized by a moderate reliance on debt alongside a strong equity base. Total assets stand at 6.6 billion CNY while total liabilities are 2.5 billion CNY, producing a debt-to-assets ratio of approximately 0.38 and an equity ratio of 0.62 (62% financed by equity). The total debt-to-equity ratio is 0.73, signaling that for every 1 CNY of equity there is 0.73 CNY of debt. Long-term borrowings have risen sharply-up 50.94% year-over-year-reflecting a strategic shift toward longer-dated financing. Interest coverage of 4.94x indicates the company generates nearly five times its interest expense in operating income, a comfortable buffer but one that merits monitoring if leverage increases.- Debt-to-equity ratio: 0.73 - moderate leverage supporting growth while retaining financial flexibility.
- Debt-to-assets ratio: ~0.38 - less than half of assets funded by liabilities, leaving collateral for creditors.
- Equity ratio: 0.62 - majority of assets financed by shareholders' equity.
- Long-term borrowings ↑ 50.94% YoY - clear tilt toward long-term funding.
- Interest coverage: 4.94x - adequate near-term ability to service interest, though sensitive to earnings volatility.
| Metric | Value | Comment |
|---|---|---|
| Total Assets | 6.6 billion CNY | Asset base supporting operations and collateral |
| Total Liabilities | 2.5 billion CNY | Includes both short-term and long-term borrowings |
| Debt-to-Assets Ratio | 0.38 | Conservative-to-moderate leverage relative to assets |
| Debt-to-Equity Ratio | 0.73 | Moderate debt relative to equity |
| Equity Ratio | 0.62 | 62% of assets financed by equity |
| Long-term Borrowings YoY Change | +50.94% | Shift toward long-term financing |
| Interest Coverage Ratio | 4.94x | Operating income covers interest ~5x |
Shandong Lukang Pharmaceutical Co.,Ltd. (600789.SS) - Liquidity and Solvency
Key metrics for assessing short-term liquidity and longer-term solvency for Shandong Lukang Pharmaceutical Co.,Ltd. (600789.SS):
- Current ratio: 1.20 - the company can cover short-term liabilities with short-term assets, but the margin is moderate.
- Quick ratio: 0.77 - indicates potential difficulty meeting immediate obligations without converting inventory to cash.
- Total cash on hand: ¥703.94 million CNY - a tangible liquidity buffer (cash ratio not specified).
- Operating cash flow (TTM): ¥266.84 million CNY - positive cash generation from core operations.
- Levered free cash flow: -¥451.72 million CNY - net cash outflow after debt servicing and capital expenditures.
- Debt-to-equity ratio: 0.73 - moderate leverage relative to equity.
- Interest coverage ratio: 4.94 - operating income covers interest expense by nearly 5x, providing reasonable ability to service debt.
| Metric | Value | Implication |
|---|---|---|
| Current Ratio | 1.20 | Moderate short-term liquidity |
| Quick Ratio | 0.77 | Less cushion without inventory |
| Total Cash | ¥703.94 million | Immediate liquid resources |
| Operating Cash Flow (TTM) | ¥266.84 million | Positive operational cash generation |
| Levered Free Cash Flow | -¥451.72 million | Cash outflows after debt and capex |
| Debt-to-Equity Ratio | 0.73 | Moderate leverage |
| Interest Coverage Ratio | 4.94 | Reasonable ability to service interest |
Relevant corporate context and strategic intent can be reviewed here: Mission Statement, Vision, & Core Values (2026) of Shandong Lukang Pharmaceutical Co.,Ltd.
Shandong Lukang Pharmaceutical Co.,Ltd. (600789.SS) - Valuation Analysis
Shandong Lukang Pharmaceutical Co.,Ltd. (600789.SS) presents a valuation profile that reflects moderate market optimism and alignment with sector norms. Key market figures point to a company that is neither deeply discounted nor richly priced relative to peers, with metrics suggesting expectations of continued earnings growth while maintaining reasonable revenue and book-value multiples.- Market capitalization: 8.33 billion CNY
- Enterprise value (EV): 10.70 billion CNY
- Trailing P/E: 43.77 - indicates the market is pricing in elevated future earnings growth or limited near-term earnings visibility
- P/S: 1.35 - market values each yuan of revenue at ~1.35 CNY
- P/B: 2.03 - equity is priced at just over twice book value, implying moderate premium to net assets
- EV/EBITDA: 14.34 - suggests the company is valued at ~14.3 times operating cash profitability
| Metric | Value | Interpretation |
|---|---|---|
| Market Capitalization | 8.33 billion CNY | Size indicator - mid-cap range on Shanghai Composite |
| Enterprise Value (EV) | 10.70 billion CNY | Reflects market cap adjusted for net debt and minority interests |
| Trailing P/E | 43.77 | High multiple, market pricing in growth or limited current earnings |
| P/S | 1.35 | Moderate revenue multiple versus pharmaceutical peers |
| P/B | 2.03 | Market values book equity at a modest premium |
| EV/EBITDA | 14.34 | Reasonable operating-earnings multiple; aligns with industry standards |
- Relative positioning: Valuation metrics broadly in line with industry standards, suggesting balanced market perception between growth prospects and risk.
- Investor signal: Elevated P/E but moderate EV/EBITDA and P/S point to expected margin improvement or above-industry growth rather than speculative overvaluation.
- Valuation drivers to monitor: Revenue growth trends, margin expansion, R&D/approval news, and changes in net debt that would affect EV-based multiples.
Shandong Lukang Pharmaceutical Co.,Ltd. (600789.SS) - Risk Factors
Key risk exposures for Shandong Lukang Pharmaceutical Co.,Ltd. (600789.SS) that investors must weigh include policy-driven pricing pressure, profitability deterioration, leverage and liquidity constraints, cash-flow stress after financing costs, and international market risks.
- Centralized drug procurement: Selected products subject to national procurement account for approximately 6.49% of 2024 revenue, exposing near-term top-line and margin risk if reimbursement or price decisions change.
- Profitability contraction: Management expects first-half 2025 net income to decline by between 59.34% and 65.98% year-on-year, signaling a sharp reduction in EPS and return on equity for the period.
- Leverage: Debt-to-equity ratio stands at 0.73, indicating meaningful reliance on debt financing versus equity capital.
- Liquidity: Quick ratio of 0.77 suggests current liquid assets may be insufficient to cover immediate liabilities without drawing on inventory or external funding.
- Cash-flow after financing: Levered free cash flow is negative at -451.72 million CNY, indicating net cash outflows after debt service and potentially constraining investment or dividend flexibility.
- International exposure: Cross-border sales and supply chains create currency, trade-policy, and geopolitical risks that can amplify revenue volatility and input-cost swings.
| Metric | Value | Implication |
|---|---|---|
| Selected products (% of 2024 revenue) | 6.49% | Directly affected by centralized procurement pricing and volume rules |
| H1 2025 net income change (y/y) | -59.34% to -65.98% | Substantial profit compression; EPS and retained earnings pressure |
| Debt-to-equity ratio | 0.73 | Moderate leverage; increases interest and refinance risk |
| Quick ratio | 0.77 | Less than 1.0 - potential difficulty meeting immediate obligations |
| Levered free cash flow | -451.72 million CNY | Negative post-debt cash flow; limits strategic flexibility |
| International risk factors | Currency & geopolitical exposure | Potential for revenue and margin volatility across markets |
- Short-term investor considerations: monitor upcoming procurement announcements, interim earnings updates clarifying the drivers of the H1 2025 net income decline, and quarterly cash-flow statements for signs of improving levered FCF or refinancing activity.
- Balance-sheet focus: track leverage trajectory (net debt trends) and any covenant metrics tied to the 0.73 D/E level; assess working-capital management given a 0.77 quick ratio.
- Strategic/operational mitigants: diversification of product mix away from procurement-vulnerable SKUs, hedging currency exposures, and cost controls to restore margins and positive levered cash flow.
More on corporate purpose and long-term strategy: Mission Statement, Vision, & Core Values (2026) of Shandong Lukang Pharmaceutical Co.,Ltd.
Shandong Lukang Pharmaceutical Co.,Ltd. (600789.SS) - Growth Opportunities
Shandong Lukang Pharmaceutical's industry positioning and recent operational highlights point to multiple scalable growth vectors across domestic and international markets. Key drivers include regulatory certifications, R&D capacity, export footprint, product diversification, and targeted government support for environmental compliance.
- Government support: received pollution-control subsidies of 14.36 million CNY, improving cash flow for sustainability projects and lowering compliance costs.
- Export reach: products shipped to over 90 countries - providing diversification of revenue sources and exposure to higher-margin regulated markets.
- R&D infrastructure: three R&D centers and five pilot platforms enable faster commercialization cycles and product pipeline expansion.
- Product mix: portfolio spans APIs, finished dosage forms (FDFs), and bio-pesticides, creating cross-selling and bundled-offer opportunities across B2B and B2C channels.
- Regulatory credentials: EU GMP and FDA approvals facilitate access to high-barrier markets and support premium pricing strategies.
- Environmental & compliance focus: subsidies and investments tied to pollution control can unlock partnerships, preferential procurement, and new market segments focused on sustainability.
| Opportunity | Evidence / Asset | Quantified Impact / Metric |
|---|---|---|
| Regulated-export expansion | EU GMP & FDA approvals | Access to >90 export markets; potential to increase ASPs (average selling prices) in regulated markets |
| Product pipeline acceleration | 3 R&D centers, 5 pilot platforms | Reduced time-to-market for new APIs/FDFs; higher probability of commercialization |
| Sustainability-driven differentiation | 14.36M CNY pollution-control subsidy + compliance investments | Lower regulatory risk; improved ESG profile for institutional investors |
| Cross-selling & portfolio leverage | APIs, FDFs, bio-pesticides | Opportunity to increase share of wallet with existing distributors and customers |
Operationalizing these opportunities will rely on execution across manufacturing scale-up, regulatory filings, and targeted commercial efforts in priority geographies. For additional context on the company's guiding principles and long-term orientation, see: Mission Statement, Vision, & Core Values (2026) of Shandong Lukang Pharmaceutical Co.,Ltd.
Shandong Lukang Pharmaceutical Co.,Ltd. (600789.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.